We are live on ! Find out more
KALV

KalVista Pharmaceuticals
KALV

Delisted

KALV was delisted on the 10th of June, 2026.

Back to rankings

69 hedge funds and large institutions have $122M invested in KalVista Pharmaceuticals in 2020 Q1 according to their latest regulatory filings, with 10 funds opening new positions, 26 increasing their positions, 21 reducing their positions, and 12 closing their positions.

New
Increased
Maintained
Reduced
Closed

24% more repeat investments, than reductions

Existing positions increased: 26 | Existing positions reduced: 21

12.27% more ownership

Funds ownership: 76.96% → 89.23% (+12%)

5% less funds holding

Funds holding: 73 → 69 (-4)

17% less first-time investments, than exits

New positions opened: 10 | Existing positions closed: 12

50% less capital invested

Capital invested by funds: $244M → $122M (-$123M)

60% less funds holding in top 10

Funds holding in top 10: 5 → 2 (-3)

Holders
69
Holders Change
-4
Holders Change %
-5.48%
% of All Funds
1.52%
Holding in Top 10
2
Holding in Top 10 Change
-3
Holding in Top 10 Change %
-60%
% of All Funds
0.04%
New
10
Increased
26
Reduced
21
Closed
12
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
VC
Vivo Capital
California
+$19.9M
2
IC
Ikarian Capital
Texas
+$9.91M
3
O
OrbiMed
New York
+$3.51M
4
Victory Capital Management
Victory Capital Management
Texas
+$3.47M
5
OM
Opaleye Management
Massachusetts
+$3.04M

Top Sellers

Rank Fund Capital Flow
1
BC
Boxer Capital
California
-$3.56M
2
ACP
Acuta Capital Partners
California
-$1.92M
3
Adage Capital Partners
Adage Capital Partners
Massachusetts
-$1.35M
4
PC
Polar Capital
United Kingdom
-$953K
5
DAM
DLD Asset Management
New York
-$891K
Name Holding Trade Value Shares
Change 		Change in
Stake
Janus Henderson Group
26
Janus Henderson Group
United Kingdom
$1.17M +$1.84M +136,392 +857%
SCM
27
Suvretta Capital Management
New York
$874K +$1.54M +114,200 New
BFM
28
Boothbay Fund Management
New York
$830K +$874K +64,743 +148%
Citadel Advisors
29
Citadel Advisors
Florida
$715K +$1.26M +93,503 New
Squarepoint
30
Squarepoint
New York
$581K -$636K -47,133 -38%
BCM
31
Bridgeway Capital Management
Texas
$462K – – –
JP Morgan Chase
32
JP Morgan Chase
New York
$454K +$543K +40,223 +210%
N
33
Nuveen
North Carolina
$433K +$232K +17,193 +44%
Renaissance Technologies
34
Renaissance Technologies
New York
$364K +$641K +47,528 New
Wells Fargo
35
Wells Fargo
California
$292K -$72.2K -5,353 -12%
Bank of New York Mellon
36
Bank of New York Mellon
New York
$268K +$944 +70 +0.2%
AA
37
ALPS Advisors
Colorado
$248K -$50.9K -3,774 -10%
BC
38
Birchview Capital
Vermont
$230K – – –
Charles Schwab
39
Charles Schwab
California
$229K – – –
Walleye Capital
40
Walleye Capital
New York
$159K +$281K +20,800 New
Bank of America
41
Bank of America
North Carolina
$153K +$211K +15,663 +359%
Morgan Stanley
42
Morgan Stanley
New York
$151K +$12.1K +896 +5%
California State Teachers Retirement System (CalSTRS)
43
California State Teachers Retirement System (CalSTRS)
California
$150K +$3.04K +225 +1%
PP
44
PDT Partners
New York
$148K -$62.8K -4,652 -19%
WMSA
45
Weiss Multi-Strategy Advisers
New York
$147K -$9.97K -739 -4%
AG
46
Algert Global
California
$144K +$65.6K +4,860 +35%
Marshall Wace
47
Marshall Wace
United Kingdom
$141K +$249K +18,454 New
GCP
48
GSA Capital Partners
United Kingdom
$128K -$675 -50 -0.3%
WG
49
Winton Group
United Kingdom
$112K -$265K -19,636 -57%
California Public Employees Retirement System
50
California Public Employees Retirement System
California
$100K – – –
1
2
3 4

KALV Hedge Fund Activity: Q1 2020 in Review

69 of the 4,539 institutional investors tracked by Wall St. Rank reported a position in KalVista Pharmaceuticals (KALV) for Q1 2020, worth a combined $122M — down 50% from $244M a quarter earlier.

Sellers outnumbered buyers: 12 funds closed out of KALV and 10 opened new positions — a net loss of 2 holders — while 21 trimmed existing stakes and 26 added.

The largest buyer was Vivo Capital, opening a new position worth an estimated $19.9M. The largest seller was Boxer Capital, exiting entirely with an estimated $3.56M sold.

  • 69 institutional investors held KalVista Pharmaceuticals (KALV) as of Q1 2020, down from 73 in Q4 2019.
  • Funds reported $122M of KalVista Pharmaceuticals stock for Q1 2020, down 50% quarter-over-quarter.
  • 10 funds opened new KalVista Pharmaceuticals positions in Q1 2020 and 12 closed out, a net change of -2 holders.
  • The largest KalVista Pharmaceuticals buyer in Q1 2020 was Vivo Capital, an estimated $19.9M added.
  • The largest KalVista Pharmaceuticals seller in Q1 2020 was Boxer Capital, an estimated $3.56M sold.

Based on aggregated 13F filings for Q1 2020.